(Q38054991)

English

Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis

scientific article published on 23 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

0 references

Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

Richard A. Hansen

2

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Gerald Gartlehner

10

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

1

object named as

Rishi J Desai

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

author name string

Jaya K Rao

3

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Tania M Wilkins

4

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Elizabeth A Harden

5

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Andrea Yuen

6

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Daniel E Jonas

7

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Robert Roubey

8

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Beth Jonas

9

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Linda Lux

11

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Katrina E Donahue

12

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

language of work or name

0 references

publication date

23 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Annals of Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

46

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

1491-1505

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

The costs of rheumatoid arthritis: an international long-term view

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Current methods of the US Preventive Services Task Force: a review of the process

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Indirect comparisons of competing interventions

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Abatacept for rheumatoid arthritis: a Cochrane systematic review

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1R203

21 January 2018

Identifiers

10.1345/APH.1R203

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38054991&oldid=1738749169"